NICE makes U-turn on new prostate cancer drug

The National Institute for Health and Clinical Excellence (NICE) has issued new draft guidance recommending a prostate cancer drug called abiraterone (brand name Zytiga) for use on the NHS in England and Wales.

Previously, NICE had said it was unable to recommend the drug.

But manufacturer Janssen submitted further information for consideration by the institute's independent appraisal committee, along with a revised patient access scheme which should save the NHS money.

ADVERTISEMENT - CONTINUE READING BELOW

As a result, NICE is now recommending abiraterone in combination with prednisone or prednisolone for the treatment of inoperable prostate cancer that has spread following treatment with docetaxel.

Sir Andrew Dillon, the institute's chief executive, said: 'We are very pleased that Janssen's submission to our consultation means that we are able to produce draft guidance recommending abiraterone.

'It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally.'

Dr Harpal Kumar, chief executive of Cancer Research UK, described the decision as 'wonderful news'.

'People's donations have allowed Cancer Research UK to fund the discovery and early development of abiraterone - now they've also helped to ensure prostate cancer patients get access to this important treatment by making their voices heard,' he added.

The materials in this web site are in no way intended to replace the professional medical care, advice, diagnosis or treatment of a doctor. The web site does not have answers to all problems. Answers to specific problems may not apply to everyone. If you notice medical symptoms or feel ill, you should consult your doctor - for further information see our Terms and conditions.